Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

This expansion will evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity.

This expansion will evaluate the combination of Decoy20 with BeiGene's PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity.

PD-1 blockade conferred benefit to certain women with surgically resectable endometrial cancer, findings presented at Society ...

It is the second drug in the PD-1/PD-L1 inhibitor class to be cleared in a subcutaneous injection form by the FDA after Roche's Tecentriq Hybreza (atezolizumab and hyaluronidase) – which got a ...

The company has mid-stage trials of the PD-1 inhibitor on the go as a combination therapy with CSF-1 inhibitor BLZ945 in solid tumours, c-Met inhibitor capmatinib in liver cancer, and Palobiofarma ...

NEW YORK – Actinium Pharmaceuticals on Tuesday said it will evaluate whether its radiotherapeutic Actimab-A can boost the efficacy of PD-1 inhibitors in PD-L1-expressing solid tumors in a new clinical ...

A team of researchers from Cleveland Clinic Genomic Medicine share insights from an early set of 19,000 patients to receive immune checkpoint inhibitor treatments for colorectal cancer in the U.S.

AbTree Biologics AG has signed an exclusive co-development and commercialization partnership with Shilpa Biologicals Pvt Ltd.